Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.73 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.73 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.73 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791211 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL25867 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL25866 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL6758767 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL19894397 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL16359955 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL24359130 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL14389708 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4942099 | 1.00 | SLC28A1 (0.73) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| Hydrochloric Acid SCHEMBL29919822 | 0.99 | SLC28A1 (0.71) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399354-A1 | PREPARATION METHOD OF 2'-SUBSTITUTED PYRIMIDINE NUCLEOSIDE | BEIJING RIBIO PHARMA CO., LTD. (CN) | 2023-12-14 | — | — | US | disclosed |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| US-20230203484-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-06-29 | — | — | US | disclosed |
| WO-2017214112-A1 | 5'-CYCLO-PHOSPHONATE MODIFIED NUCLEOTIDES | Arrowhead Pharmaceuticals, Inc. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170275621-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20170275626-A1 | MODIFIED DOUBLE-STRANDED RNA AGENTS | BANK OF AMERICA, N.A. | 2017-09-28 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2013052523-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-04-11 | — | — | WO | disclosed |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | SLC28A1 80/4885SLC28A2 66/4885SLC29A1 41/4885 |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | SLC28A1 317/4885SLC28A2 259/4885SLC29A1 239/4885 |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | NSUN2, RNMT, RNGTT | SLC28A1 222/4885SLC28A2 214/4885SLC29A1 183/4885 |
| US-20170275621-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | SLC28A1 2387/4885SLC28A2 2412/4885SLC29A1 931/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | SLC28A1 317/4885SLC28A2 259/4885SLC29A1 239/4885 |
| US-20230203087-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, ALKBH1 | SLC28A1 354/4885SLC28A2 248/4885SLC29A1 249/4885 |
| US-20230399354-A1 | PREPARATION METHOD OF 2'-SUBSTITUTED PYRIMIDINE NUCLEOSIDE | UMPS, TYMP, DPYD | SLC28A1 81/4885SLC28A2 27/4885SLC29A1 14/4885 |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | SLC28A1 139/4885SLC28A2 146/4885SLC29A1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.